Ditiocarb sodium
PreclinicalSmall molecule
Ditiocarb sodium is one of 45 small molecule programs targeting CAR. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in CAR
#DrugCompanyPhaseTrials
1Isopto Carpine
AAdvanz Pharma
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Floxin
WWim Janssens
Phase 3
Pelacarsen
NovartisPhase 3
L-Carnitine
IIperboreal Pharma Srl
Phase 3
Tegretol
NovartisPhase 1
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Tylenol
KKenvue Brands
Phase 2
Diamox
TevaPhase 1
Trileptal
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ditiocarb sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details